CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| NRG-HN001 | RTOG | Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) | Adult CIRB - Late Phase Emphasis | Available to Open |
| URCC-22053 | NCORP-University of Rochester Cancer Center | High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients | Cancer Prevention and Control CIRB | Available to Open |
| EAY191-A3 | Alliance | A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10104 | ETCTN | A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer. | Adult CIRB - Early Phase Emphasis | Available to Open |
| AREN0534 | COG | Treatment for Patients with Bilateral; Multicentric; or Bilaterally-Predisposed Unilateral Wilms Tumor: A Groupwide Phase III Study | Pediatric CIRB | Available to Open |
| 10367 | ETCTN | A Phase 1b Study with Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML) | Adult CIRB - Early Phase Emphasis | Available to Open |
| AALL1821 | COG | A Phase 2 Study of Blinatumomab (NSC# 765986, IND #125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years with First Relapse | Pediatric CIRB | Available to Open |
| A011801 | Alliance | The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinb | Adult CIRB - Late Phase Emphasis | Available to Open |
| S2005 | SWOG | A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoclax in Previously Untreated Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-GU007 | NRG | Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) | Adult CIRB - Late Phase Emphasis | Available to Open |